Stock IMCR IMMUNOCORE HOLDINGS PLC
Add to a list
To use this feature you must be a member
Log inSign up

All News Immunocore Holdings plc

Equities

IMCR

US45258D1054

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
59.46 USD +0.69% Intraday chart for Immunocore Holdings plc +2.52% -12.97%
04-29 Leerink Partners Starts Immunocore Holdings With Outperform Rating, $74 Price Target MT
03-21 Immunocore Holdings Files Mixed-Securities Shelf Registration MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Avacta Group plc - Christina Coughlin, MD, PhD, appointed Chief Executive Officer of Avacta Group
AQ
Leerink Partners Starts Immunocore Holdings With Outperform Rating, $74 Price Target
MT
Immunocore announces upcoming presentation and posters at ASCO 2024
GL
Immunocore to present at upcoming investor conferences
GL
Immunocore Holdings Files Mixed-Securities Shelf Registration
MT
Transcript : Immunocore Holdings plc Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:30 AM
Immunocore presented two posters at CROI 2024
GL
Mizuho Securities Raises Immunocore Price Target to $90 From $86, Maintains Buy Rating
MT
Immunocore to present at upcoming investor conferences
GL
Oppenheimer Adjusts Immunocore Price Target to $87 From $85, Maintains Outperform Rating
MT
Immunocore Holdings' Q4 Net Loss Narrows, Revenue Rises
MT
Transcript : Immunocore Holdings plc, Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (IMCR) IMMUNOCORE HOLDINGS LIMITED Reports Q4 Revenue $70.2M, vs. Street Est of $68.5M
MT
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
GL
Immunocore Holdings plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Immunocore Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Immunocore Collaborates With Bristol Myers Squibb in Advanced Cutaneous Melanoma Trial
MT
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
GL
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
GL
Mizuho Raises Price Target on Immunocore to $86 From $72 Ahead of Q4 2023 Earnings Announcement, Reiterates Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMCR Stock
  4. News Immunocore Holdings plc